[{"id":"3238c54f-2a9a-4ab3-baf8-2db814a9281f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04196023","created_at":"2021-01-18T20:27:00.858Z","updated_at":"2024-07-02T16:35:02.436Z","phase":"","brief_title":"Ca:Mg Ratio and Cognitive Function","source_id_and_acronym":"NCT04196023","lead_sponsor":"Vanderbilt University Medical Center","biomarkers":" APOE","pipe":"","alterations":" ","tags":["APOE"],"overall_status":"Completed","enrollment":" Enrollment 129","initiation":"Initiation: 12/12/2012","start_date":" 12/12/2012","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2024-05-21"},{"id":"ca8f6678-d67e-49f0-9945-dcd42f545951","acronym":"GERFHS-III","url":"https://clinicaltrials.gov/study/NCT00930280","created_at":"2021-01-18T03:36:09.278Z","updated_at":"2024-07-02T16:35:27.203Z","phase":"","brief_title":"Genetic and Environmental Risk Factors for Hemorrhagic Stroke-GERFHS III","source_id_and_acronym":"NCT00930280 - GERFHS-III","lead_sponsor":"University of Cincinnati","biomarkers":" APOE","pipe":"","alterations":" ","tags":["APOE"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1260","initiation":"Initiation: 07/01/2008","start_date":" 07/01/2008","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-12-04"},{"id":"e829fb14-3e34-428f-ab59-c6d18b40607d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02922764","created_at":"2021-01-18T14:21:03.943Z","updated_at":"2024-07-02T16:35:29.345Z","phase":"Phase 1","brief_title":"A Study of RGX-104 in Patients With Advanced Lung \u0026 Endometrial Cancer","source_id_and_acronym":"NCT02922764","lead_sponsor":"Inspirna, Inc.","biomarkers":" EGFR • ALK • CTLA4 • APOE","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • ALK • CTLA4 • APOE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • abequolixron (RGX-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-11-14"},{"id":"ff145ca5-700f-49c0-b8a0-de84d8f88a34","acronym":"DL-MAFLD-TCM","url":"https://clinicaltrials.gov/study/NCT04853082","created_at":"2021-04-21T11:53:36.247Z","updated_at":"2024-07-02T16:36:21.697Z","phase":"Phase 1","brief_title":"Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution","source_id_and_acronym":"NCT04853082 - DL-MAFLD-TCM","lead_sponsor":"Hongsheng Tan","biomarkers":" APOE","pipe":"","alterations":" ","tags":["APOE"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 02/22/2021","start_date":" 02/22/2021","primary_txt":" Primary completion: 10/25/2021","primary_completion_date":" 10/25/2021","study_txt":" Completion: 10/25/2021","study_completion_date":" 10/25/2021","last_update_posted":"2021-11-02"},{"id":"9ae33455-2ccd-4694-baa3-c5a45d899f04","acronym":"","url":"https://clinicaltrials.gov/study/NCT04364451","created_at":"2021-01-18T21:05:38.311Z","updated_at":"2024-07-02T16:36:45.566Z","phase":"","brief_title":"Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Eukaemia During Therapy With L - Asparaginase.","source_id_and_acronym":"NCT04364451","lead_sponsor":"Aristotle University Of Thessaloniki","biomarkers":" APOA1 • APOB • APOE • LPL","pipe":"","alterations":" ","tags":["APOA1 • APOB • APOE • LPL"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 08/31/2022","primary_completion_date":" 08/31/2022","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2020-04-28"},{"id":"c288adad-cfb3-4401-9a6f-a4cddbc11475","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452436","created_at":"2021-01-18T17:01:31.045Z","updated_at":"2024-07-02T16:36:47.685Z","phase":"","brief_title":"Testosterone, Cognition, Ageing, and Cancer","source_id_and_acronym":"NCT03452436","lead_sponsor":"University of Aarhus","biomarkers":" APOE • BDNF • COMT","pipe":"","alterations":" ","tags":["APOE • BDNF • COMT"],"overall_status":"Completed","enrollment":" Enrollment 133","initiation":"Initiation: 02/12/2018","start_date":" 02/12/2018","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2020-03-25"},{"id":"35e608cc-539c-4ac1-a89a-c289c5e8a0c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01522404","created_at":"2021-01-18T06:24:18.792Z","updated_at":"2024-07-02T16:36:57.820Z","phase":"Phase 2","brief_title":"Effects of Atomoxetine in Mild Cognitive Impairment","source_id_and_acronym":"NCT01522404","lead_sponsor":"Emory University","biomarkers":" IL1A • APOE • CYP2D6","pipe":"","alterations":" ","tags":["IL1A • APOE • CYP2D6"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 10/31/2017","primary_completion_date":" 10/31/2017","study_txt":" Completion: 06/30/2018","study_completion_date":" 06/30/2018","last_update_posted":"2019-07-23"},{"id":"64869ade-a6c9-483a-ac3a-c7d531966c14","acronym":"","url":"https://clinicaltrials.gov/study/NCT01601314","created_at":"2021-01-18T06:50:52.181Z","updated_at":"2024-07-02T16:37:14.756Z","phase":"Phase 3","brief_title":"Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients","source_id_and_acronym":"NCT01601314","lead_sponsor":"Sara Varea","biomarkers":" APOE • S100B","pipe":"","alterations":" ","tags":["APOE • S100B"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2018-01-17"},{"id":"d25d50be-ee2c-48b8-96ec-b4c938ec191b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00634270","created_at":"2021-01-18T02:21:35.320Z","updated_at":"2024-07-02T16:37:16.263Z","phase":"Phase 2","brief_title":"A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas","source_id_and_acronym":"NCT00634270","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" NF1 • APOE","pipe":"","alterations":" ","tags":["NF1 • APOE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 04/01/2008","start_date":" 04/01/2008","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2017-11-17"}]